Clinical Research Advances in Pharmacogenetics and Pharmacogenomics

A Special Issue of Genes (ISSN 2073-4425) belonging to the section "Pharmacogenetics".

Deadline for manuscript submissions: 20 September 2026 | Viewed by 943

Editor


E-Mail Website
Guest Editor
1. Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital, Frankfurt am Main, Germany
2. Department of Mental Health, Varisano Hospital Frankfurt Hoechst, Frankfurt am Main, Germany
Interests: pharmacogenetics; pharmacogenomics; pharmaceutical care; therapeutic drug monitoring; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the groundbreaking advances in pharmacogenetics and pharmacogenomics, which are pivotal in shaping the landscape of clinical research and personalized medicine. As we delve into the intricate interactions between genetics, gender, and drug responses, this edition highlights innovative methodologies and translational applications that aim to improve therapeutic outcomes and minimize adverse effects across diverse demographics.

With the rapid emergence of genetic testing technologies and bioinformatics, we are witnessing a paradigm shift in how medications are prescribed, moving from a “one-size-fits-all” approach to tailored therapies that consider individual genetic profiles and gender-specific responses. Moreover, this Issue brings together leading researchers and clinicians who discuss the latest findings, challenges, and future directions in the field, ranging from genetic markers influencing drug metabolism to the role of pharmacogenomics in managing chronic diseases and incorporating gender considerations to address disparities in treatment efficacy.

By fostering interdisciplinary collaboration and knowledge exchange, we aspire to enhance understanding and implementation of personalized treatment strategies that reflect both genetic and gender-specific factors, ultimately contributing to more effective and safer pharmacological interventions for diverse patient populations. This Special Issue serves as a vital resource for researchers, clinicians, and policymakers invested in advancing clinical practices through pharmacogenetic and gender-based insights.

Prof. Dr. Martina Hahn
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacogenetics
  • pharmacogenomics
  • personalized medicine
  • gender medicine
  • genetic testing
  • drug response
  • therapeutic outcomes
  • adverse drug reactions
  • clinical research
  • genetic markers
  • precision therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 365 KB  
Article
Preliminary Evidence for Sex Differences in CYP2C19 Metabolic Capacity During Psychotropic Drug Treatment
by Janina Eiberger, Heike Weber, Andreas Reif, Jürgen Deckert, Sebastian Walther, Martina Hahn and Maike Scherf-Clavel
Genes 2026, 17(6), 718; https://doi.org/10.3390/genes17060718 - 21 Jun 2026
Viewed by 590
Abstract
Background/Objectives: Sex-specific differences in the pharmacokinetics of psychotropic drugs are gaining increasing clinical relevance, but only limited data are currently available on sex-specific effects within genetically defined metabolizer phenotype categories. The objective of this study was to assess genotype-dependent sex differences in [...] Read more.
Background/Objectives: Sex-specific differences in the pharmacokinetics of psychotropic drugs are gaining increasing clinical relevance, but only limited data are currently available on sex-specific effects within genetically defined metabolizer phenotype categories. The objective of this study was to assess genotype-dependent sex differences in the metabolic capacity of the drug-metabolizing enzymes CYP2D6 and CYP2C19. Methods: Statistical analyses were performed using linear mixed-effects models with subject-level random intercepts to account for repeated therapeutic drug monitoring (TDM) measurements. Venlafaxine and risperidone were used as probe drugs to find differences in the metabolic capacity of CYP2D6 and escitalopram for CYP2C19. Pharmacokinetic surrogate parameters were the metabolite-to-parent ratio (MPR) for venlafaxine and risperidone and the dose-corrected serum concentration (CD) for escitalopram. Models included sex, metabolizer phenotype, and their interaction, adjusted for age and creatinine production rate (CPR). Sex-specific differences within phenotype groups were assessed using estimated marginal means. Results: Among venlafaxine samples (N = 117) and risperidone samples (N = 73), no significant sex-specific differences in MPR were observed within CYP2D6 metabolizer groups. For escitalopram samples (N = 51), a significant sex difference was observed among CYP2C19 normal metabolizers (NMs), with higher CD in males compared to females. Conclusions: Exploratory analyses suggested a higher metabolic capacity in CYP2C19 NM females treated with escitalopram. Due to the limited sample size, however, this finding should be considered hypothesis-generating. Future studies in larger samples are needed to corroborate whether sex and other factors modulate the metabolic capacity of CYP2C19, e.g., by epigenetic mechanisms. Full article
(This article belongs to the Special Issue Clinical Research Advances in Pharmacogenetics and Pharmacogenomics)
Show Figures

Figure 1

Back to TopTop